CYP1A2 polymorphism may contribute to agomelatine-induced acute liver injury: Case report and review of the literature.

ABSTRACT:

Rationale

Liver function monitoring is recommended when agomelatine is prescribed, although liver enzymes are not considered predictive biomarkers. Most patients present with acute liver injury, with only a few presenting with levels of liver enzymes that are over 30 times the upper limit of normal. The patient-specific risk factors that are associated with liver injury remain unclear. Thus, this report provides new insights into the mechanism of agomelatine-induced acute hepatocellular injury based on cytochrome P450 family 1 subfamily A member 2 (CYP1A2) polymorphism.

Patient concerns

We present a case of acute hepatocellular injury in a 75-year-old man who was taking agomelatine at a dose of 50 mg/qn. All hepatitis virus test results were negative. No history of liver dis

SUBMITTER: Wang S 

PROVIDER: S-EPMC10545369 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature